Editorial Policy

Biotech Strategy Blog provides commentary and insight on new product development in the pharma and biotech industries with a focus on oncology, hematology, immunotherapy and immuno-oncology.

Our cancer conference coverage focuses on scientific and clinical data presented at medical and scientific meetings run by societies and organizations such as AAI, AACR, ASCO, ASGCT, ASBMT, ASH, AUA, EACR, EAU, EBMT, ECCO, EHA, ESMO, SABCS & SITC.

Occasionally covered are themes such as innovation, nanotechnology, regenerative medicine, strategic issues in the biotechnology industry and promising scientific research in other therapeutic areas.

All the content is editorially independent, no post is sponsored and no paid advertising is accepted. Posts reflect the opinion of the author and not those of any employer or company. 

Unsolicited guest posts are not accepted. 

Some content (“Premium Content”) requires payment of a fee to access. All posts from 2010 and 2011 are free and open access.

By accessing or using this website, you accept and agree to the Terms of Use. These should be really carefully as upon acceptance they form a contract that governs your use of this site and purchase of Premium Content. If you do not wish to accept the Terms of Use you should not access or use this website.

Editor & Oncology Lead Writer

Sally Church with @Gene_Antibody at ASCO 2014

Credit: @Gene_Antibody at ASCO14

From September 2013, Sally Church, PhD has become the Editor of Biotech Strategy Blog and lead writer for oncology related content.

Sally is widely recognised as an oncology new products expert. She has appeared on CNBC and is frequently quoted by media outlets.

Back in 2011, Sally was named as one of the Top 50 women on Twitter, where as @MaverickNY she is a frequent commentator on oncology drug development. Sally uses the author name “MaverickNY” to identify her posts on this blog.

Since 2006, Sally has written over 1,000 posts on the widely acclaimed Pharma Strategy Blog which showcased her knowledge of cancer biology and new product development. As part of her “Making a Difference” series she regularly conducted interviews with oncology thought leaders. Sally now focuses her attention on writing for Biotech Strategy Blog.

Gleevec on cover of Time Magazine

With over 20 years experience in the pharmaceutical industry in the UK & United States, Sally has held executive positions in sales, marketing and new product development, and has received numerous business achievement awards.

At Novartis Oncology she co-led the initial US launches of Gleevec® in CML and GIST.

After 10 years as a successful consultant advising many of the world’s leading pharmaceutical and emerging biotech companies on strategic marketing and oncology new product development, Sally is now a full-time digital media entrepreneur through her company, Blue Ice Publishing LLC.

In addition to leading the oncology content on Biotech Strategy Blog, Sally is also executive producer of the Novel Targets Podcast, (@TargetsPodcast).

Sally’s qualifications includes a PhD from Kings College London, MBA from Rutgers, Master of Science in Human & Applied Physiology and undergraduate degree in Sports Science. She has also undertaken executive education in finance at Harvard Business School. A keen sportswoman, Sally has played at national and county level in cricket and hockey in the UK.

She devotes some of her spare time to charitable cancer causes and sits on the board of directors of a non-profit organization, GRACE (Global Resource for Advancing Cancer Education) which focuses primarily on lung cancer education.

Sally is a member of the National Association of Science Writers (NASW) and Association of Health Care Journalists (AHCJ).

At Health Journalism 2017 Sally spoke on Friday, April 21 2017 in a session moderated by Scott Hensley (NPR) on “How cancer patients are changing clinical trials.”